Intersect ENT Inc (XENT) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its holdings in Intersect ENT Inc (NASDAQ:XENT) by 8.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,523 shares of the medical equipment provider’s stock after selling 7,217 shares during the quarter. Mutual of America Capital Management LLC owned about 0.28% of Intersect ENT worth $2,674,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of XENT. Jennison Associates LLC lifted its holdings in shares of Intersect ENT by 22.4% in the 4th quarter. Jennison Associates LLC now owns 2,036,202 shares of the medical equipment provider’s stock worth $65,973,000 after acquiring an additional 372,320 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Intersect ENT by 39.4% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 160,883 shares of the medical equipment provider’s stock valued at $5,213,000 after buying an additional 45,444 shares in the last quarter. Bank of Montreal Can bought a new stake in Intersect ENT during the 4th quarter valued at about $135,000. Simplex Trading LLC bought a new stake in Intersect ENT during the 4th quarter valued at about $242,000. Finally, GSA Capital Partners LLP bought a new stake in Intersect ENT during the 3rd quarter valued at about $926,000. 87.44% of the stock is owned by institutional investors and hedge funds.

Intersect ENT Inc (XENT) traded down $0.10 on Friday, hitting $37.70. 153,127 shares of the company traded hands, compared to its average volume of 295,461. Intersect ENT Inc has a 1 year low of $12.50 and a 1 year high of $38.30. The firm has a market cap of $1,110.49, a PE ratio of -59.84 and a beta of 0.79.

In other news, insider Gwen R. Carscadden sold 10,000 shares of the company’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $34.35, for a total transaction of $343,500.00. Following the completion of the sale, the insider now owns 13,856 shares of the company’s stock, valued at $475,953.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Lisa D. Earnhardt sold 10,685 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $31.87, for a total transaction of $340,530.95. Following the sale, the insider now directly owns 487,868 shares of the company’s stock, valued at approximately $15,548,353.16. The disclosure for this sale can be found here. Insiders have sold 186,510 shares of company stock valued at $6,172,429 over the last 90 days. 13.70% of the stock is currently owned by company insiders.

Several equities research analysts have recently commented on XENT shares. Zacks Investment Research downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Northland Securities reissued a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a research report on Friday, November 3rd. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research report on Tuesday, November 7th. BidaskClub downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, Canaccord Genuity reissued a “buy” rating and set a $36.00 target price on shares of Intersect ENT in a research report on Monday, December 11th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $33.38.

TRADEMARK VIOLATION NOTICE: “Intersect ENT Inc (XENT) Shares Sold by Mutual of America Capital Management LLC” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://weekherald.com/2018/02/18/intersect-ent-inc-xent-shares-sold-by-mutual-of-america-capital-management-llc.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply